AU2002338734B2 - Use of phosphorodiesterase IV inhibitors - Google Patents
Use of phosphorodiesterase IV inhibitors Download PDFInfo
- Publication number
- AU2002338734B2 AU2002338734B2 AU2002338734A AU2002338734A AU2002338734B2 AU 2002338734 B2 AU2002338734 B2 AU 2002338734B2 AU 2002338734 A AU2002338734 A AU 2002338734A AU 2002338734 A AU2002338734 A AU 2002338734A AU 2002338734 B2 AU2002338734 B2 AU 2002338734B2
- Authority
- AU
- Australia
- Prior art keywords
- ethyl
- ole
- dihydro
- thiadiazin
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003112 inhibitor Substances 0.000 title 1
- -1 methylenedioxy Chemical group 0.000 claims description 131
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 104
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 85
- 150000001875 compounds Chemical class 0.000 claims description 80
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 74
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 63
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 63
- 125000004432 carbon atom Chemical group C* 0.000 claims description 51
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 20
- 208000030507 AIDS Diseases 0.000 claims description 18
- 206010027476 Metastases Diseases 0.000 claims description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims description 17
- 201000006417 multiple sclerosis Diseases 0.000 claims description 17
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 17
- 201000001320 Atherosclerosis Diseases 0.000 claims description 16
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 16
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 16
- 208000023275 Autoimmune disease Diseases 0.000 claims description 15
- 230000002757 inflammatory effect Effects 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- HTZVRAPOLYURTG-UHFFFAOYSA-N n-[4-[[5-(3,4-dimethoxyphenyl)-6-ethyl-2-oxo-6h-1,3,4-thiadiazin-3-yl]methyl]phenyl]-2,2,2-trifluoroacetamide Chemical compound N1=C(C=2C=C(OC)C(OC)=CC=2)C(CC)SC(=O)N1CC1=CC=C(NC(=O)C(F)(F)F)C=C1 HTZVRAPOLYURTG-UHFFFAOYSA-N 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- DTYIPKIMTNWGEC-UHFFFAOYSA-N 3-(diethylamino)propyl n-[4-[[5-(3,4-dimethoxyphenyl)-2-oxo-6h-1,3,4-thiadiazin-3-yl]methyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCCCN(CC)CC)=CC=C1CN1C(=O)SCC(C=2C=C(OC)C(OC)=CC=2)=N1 DTYIPKIMTNWGEC-UHFFFAOYSA-N 0.000 claims description 2
- FGQYYCHKYIREFI-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methyl]-5-(3,4-dimethoxyphenyl)-6-ethyl-6h-1,3,4-thiadiazin-2-one Chemical compound N1=C(C=2C=C(OC)C(OC)=CC=2)C(CC)SC(=O)N1CC1=C(Cl)C=CC=C1Cl FGQYYCHKYIREFI-UHFFFAOYSA-N 0.000 claims description 2
- JPJFJTANAMGIFE-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-6-ethyl-3-[(4-methoxyphenyl)methyl]-6h-1,3,4-thiadiazin-2-one Chemical compound N1=C(C=2C=C(OC)C(OC)=CC=2)C(CC)SC(=O)N1CC1=CC=C(OC)C=C1 JPJFJTANAMGIFE-UHFFFAOYSA-N 0.000 claims description 2
- GWVPBGLOGIVWER-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-6-ethyl-3-[(4-nitrophenyl)methyl]-6h-1,3,4-thiadiazin-2-one Chemical compound N1=C(C=2C=C(OC)C(OC)=CC=2)C(CC)SC(=O)N1CC1=CC=C([N+]([O-])=O)C=C1 GWVPBGLOGIVWER-UHFFFAOYSA-N 0.000 claims description 2
- KQUGNOYYBNPZBP-UHFFFAOYSA-N 5-[4-(difluoromethoxy)-3-methoxyphenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one Chemical compound CCC1SC(=O)NN=C1C1=CC=C(OC(F)F)C(OC)=C1 KQUGNOYYBNPZBP-UHFFFAOYSA-N 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 230000000711 cancerogenic effect Effects 0.000 claims description 2
- 231100000315 carcinogenic Toxicity 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- RQPOEGOXCVKURG-UHFFFAOYSA-N ethyl n-[4-[[3-(3,4-dimethoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1CN1C(=O)CCC(C=2C=C(OC)C(OC)=CC=2)=N1 RQPOEGOXCVKURG-UHFFFAOYSA-N 0.000 claims description 2
- YYLMPPQOOUHPPJ-UHFFFAOYSA-N n-[3-[[3-(3,4-dimethoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CCC1=O)=NN1CC1=CC=CC(NC(C)=O)=C1 YYLMPPQOOUHPPJ-UHFFFAOYSA-N 0.000 claims description 2
- NZUBMTQQNISIDZ-UHFFFAOYSA-N n-[4-[[5-(3,4-dimethoxyphenyl)-2-oxo-6h-1,3,4-thiadiazin-3-yl]methyl]phenyl]pyridine-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CSC1=O)=NN1CC(C=C1)=CC=C1NC(=O)C1=CC=CN=C1 NZUBMTQQNISIDZ-UHFFFAOYSA-N 0.000 claims description 2
- BCINSFUJSPEZRI-UHFFFAOYSA-N n-[4-[[5-(3,4-dimethoxyphenyl)-6-ethyl-2-oxo-6h-1,3,4-oxadiazin-3-yl]methyl]phenyl]pyridine-3-carboxamide Chemical compound N1=C(C=2C=C(OC)C(OC)=CC=2)C(CC)OC(=O)N1CC(C=C1)=CC=C1NC(=O)C1=CC=CN=C1 BCINSFUJSPEZRI-UHFFFAOYSA-N 0.000 claims description 2
- RWGZZBUQZUXTCC-UHFFFAOYSA-N n-[4-[[5-(3,4-dimethoxyphenyl)-6-ethyl-2-oxo-6h-1,3,4-thiadiazin-3-yl]methyl]phenyl]acetamide Chemical compound N1=C(C=2C=C(OC)C(OC)=CC=2)C(CC)SC(=O)N1CC1=CC=C(NC(C)=O)C=C1 RWGZZBUQZUXTCC-UHFFFAOYSA-N 0.000 claims description 2
- JEHXGPPOGAKEIP-UHFFFAOYSA-N n-[[5-(3,4-dimethoxyphenyl)-2-oxo-6h-1,3,4-thiadiazin-3-yl]-phenylmethyl]pyridine-4-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CSC1=O)=NN1C(C=1C=CC=CC=1)NC(=O)C1=CC=NC=C1 JEHXGPPOGAKEIP-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- KLMXLJACPQPBDG-UHFFFAOYSA-N n-[4-[[5-(3-ethoxy-4-methoxyphenyl)-2-oxo-6h-1,3,4-thiadiazin-3-yl]methyl]phenyl]pyridine-3-carboxamide Chemical compound C1=C(OC)C(OCC)=CC(C=2CSC(=O)N(CC=3C=CC(NC(=O)C=4C=NC=CC=4)=CC=3)N=2)=C1 KLMXLJACPQPBDG-UHFFFAOYSA-N 0.000 claims 2
- LEURGHMXWSUXTF-UHFFFAOYSA-N 5-[4-(difluoromethoxy)-3-methoxyphenyl]-3,6-dihydro-1,3,4-thiadiazin-2-one Chemical compound C1=C(OC(F)F)C(OC)=CC(C=2CSC(=O)NN=2)=C1 LEURGHMXWSUXTF-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 101100234002 Drosophila melanogaster Shal gene Proteins 0.000 claims 1
- 235000015076 Shorea robusta Nutrition 0.000 claims 1
- 244000166071 Shorea robusta Species 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- NIHJXZMNNAHEEV-UHFFFAOYSA-N ethyl n-[4-[[3-(3,4-dimethoxyphenyl)-4-ethyl-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1CN1C(=O)CC(CC)C(C=2C=C(OC)C(OC)=CC=2)=N1 NIHJXZMNNAHEEV-UHFFFAOYSA-N 0.000 claims 1
- FCEFLSGAPFCWGS-UHFFFAOYSA-N n-[3-[[3-(3,4-dimethoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]methanesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CCC1=O)=NN1CC1=CC=CC(NS(C)(=O)=O)=C1 FCEFLSGAPFCWGS-UHFFFAOYSA-N 0.000 claims 1
- VULAEEDZQSJNRT-UHFFFAOYSA-N n-[4-[[5-(3,4-dimethoxyphenyl)-2-oxo-6h-1,3,4-thiadiazin-3-yl]methyl]phenyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CSC1=O)=NN1CC1=CC=C(NC(C)=O)C=C1 VULAEEDZQSJNRT-UHFFFAOYSA-N 0.000 claims 1
- UZFKGQZERPKMQX-UHFFFAOYSA-N n-[4-[[5-(3,4-dimethoxyphenyl)-2-oxo-6h-1,3,4-thiadiazin-3-yl]methyl]phenyl]pyridine-4-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CSC1=O)=NN1CC(C=C1)=CC=C1NC(=O)C1=CC=NC=C1 UZFKGQZERPKMQX-UHFFFAOYSA-N 0.000 claims 1
- 239000004576 sand Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 139
- ORSUMIZRRGPJBR-UHFFFAOYSA-N 4,5-dihydro-1h-pyridazin-6-one Chemical compound O=C1CCC=NN1 ORSUMIZRRGPJBR-UHFFFAOYSA-N 0.000 description 29
- TVPRCLHSULCNLV-UHFFFAOYSA-N pyridazin-3-one Chemical compound O=C1C=CC=N[N]1 TVPRCLHSULCNLV-UHFFFAOYSA-N 0.000 description 19
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 18
- 229940080818 propionamide Drugs 0.000 description 18
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 13
- 235000003930 Aegle marmelos Nutrition 0.000 description 10
- 244000058084 Aegle marmelos Species 0.000 description 10
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 8
- CFGDUGSIBUXRMR-UHFFFAOYSA-N 1,2-dihydropyrrol-2-ide Chemical compound C=1C=[C-]NC=1 CFGDUGSIBUXRMR-UHFFFAOYSA-N 0.000 description 7
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- MJTFALHLZWUAGR-UHFFFAOYSA-N 2-ethyl-4,5-dihydropyridazin-3-one Chemical compound CCN1N=CCCC1=O MJTFALHLZWUAGR-UHFFFAOYSA-N 0.000 description 5
- XMFAAIVNNSITSV-UHFFFAOYSA-N 1,3-dihydropyrrol-3-ide Chemical compound C1=CNC=[C-]1 XMFAAIVNNSITSV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 4
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- UVHIZWPJDCBXFK-UHFFFAOYSA-N 4-ethyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CCC1CC(=O)NN=C1 UVHIZWPJDCBXFK-UHFFFAOYSA-N 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 241001024304 Mino Species 0.000 description 3
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 229940047583 cetamide Drugs 0.000 description 3
- LYZCWDIVOAXKQP-UHFFFAOYSA-N diazinan-3-one Chemical compound O=C1CCCNN1 LYZCWDIVOAXKQP-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- GNPWYHFXSMINJQ-UHFFFAOYSA-N 1,2-dimethyl-3-(1-phenylethyl)benzene Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CC=CC=C1 GNPWYHFXSMINJQ-UHFFFAOYSA-N 0.000 description 2
- WTGUUGJZRZUIAU-UHFFFAOYSA-N 1,3,4-thiadiazin-2-one Chemical compound O=C1N=NC=CS1 WTGUUGJZRZUIAU-UHFFFAOYSA-N 0.000 description 2
- LPVPITJSBXSDHT-UHFFFAOYSA-N 3,6-dihydro-1,3,4-thiadiazin-2-one Chemical compound O=C1NN=CCS1 LPVPITJSBXSDHT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102000018594 Tumour necrosis factor Human genes 0.000 description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 101150032584 oxy-4 gene Proteins 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- PGOYHKFWHCPMGL-UHFFFAOYSA-N 2-[(2-aminophenyl)methyl]-6-(3,4-dimethoxyphenyl)-4,5-dihydropyridazin-3-one Chemical compound C1=C(OC)C(OC)=CC=C1C(CCC1=O)=NN1CC1=CC=CC=C1N PGOYHKFWHCPMGL-UHFFFAOYSA-N 0.000 description 1
- UQZPGHOJMQTOHB-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)-n-ethylethanamine Chemical compound ClCCN(CC)CCCl UQZPGHOJMQTOHB-UHFFFAOYSA-N 0.000 description 1
- XFOHCLJOWFIWRP-UHFFFAOYSA-N 3,6-dihydro-1,3,4-oxadiazin-2-one Chemical compound O=C1NN=CCO1 XFOHCLJOWFIWRP-UHFFFAOYSA-N 0.000 description 1
- JKMBTWOATVESDI-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NNC(=O)CC1 JKMBTWOATVESDI-UHFFFAOYSA-N 0.000 description 1
- DTBDAFLSBDGPEA-UHFFFAOYSA-N 3-Methylquinoline Natural products C1=CC=CC2=CC(C)=CN=C21 DTBDAFLSBDGPEA-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- WIVMBQZZIYHVCZ-UHFFFAOYSA-N 6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one Chemical compound CCC1SC(=O)NN=C1 WIVMBQZZIYHVCZ-UHFFFAOYSA-N 0.000 description 1
- CRVAECICDQAMRA-UHFFFAOYSA-N 6-ethyl-5-[3-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-one Chemical compound CCC1SC(=O)NN=C1C1=CC=C(OC(F)(F)F)C(OC)=C1 CRVAECICDQAMRA-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000012658 Skin autoimmune disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- YIFNXTKNYSTOQN-UHFFFAOYSA-N n-[4-[2-[3-(3,4-dimethoxyphenyl)-4-ethyl-6-oxo-4,5-dihydropyridazin-1-yl]ethyl]phenyl]-2,2,3,3,3-pentafluoropropanamide Chemical compound N1=C(C=2C=C(OC)C(OC)=CC=2)C(CC)CC(=O)N1CCC1=CC=C(NC(=O)C(F)(F)C(F)(F)F)C=C1 YIFNXTKNYSTOQN-UHFFFAOYSA-N 0.000 description 1
- SZJJLLKKGPKBQX-UHFFFAOYSA-N n-[4-[2-[3-(3,4-dimethoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]ethyl]phenyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CCC1=O)=NN1CCC1=CC=C(NC(C)=O)C=C1 SZJJLLKKGPKBQX-UHFFFAOYSA-N 0.000 description 1
- GIIRMKFFPDJRKT-UHFFFAOYSA-N n-[4-[2-[3-(3,4-dimethoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]ethyl]phenyl]pyrazine-2-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CCC1=O)=NN1CCC(C=C1)=CC=C1NC(=O)C1=CN=CC=N1 GIIRMKFFPDJRKT-UHFFFAOYSA-N 0.000 description 1
- XDGXAZPROPKMKW-UHFFFAOYSA-N n-[4-[[3-(3,4-dimethoxyphenyl)-4-ethyl-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]-2,2,2-trifluoroacetamide Chemical compound N1=C(C=2C=C(OC)C(OC)=CC=2)C(CC)CC(=O)N1CC1=CC=C(NC(=O)C(F)(F)F)C=C1 XDGXAZPROPKMKW-UHFFFAOYSA-N 0.000 description 1
- YMAJLELSVNAWDQ-UHFFFAOYSA-N n-[4-[[3-(3,4-dimethoxyphenyl)-4-ethyl-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]butanamide Chemical compound C1=CC(NC(=O)CCC)=CC=C1CN1C(=O)CC(CC)C(C=2C=C(OC)C(OC)=CC=2)=N1 YMAJLELSVNAWDQ-UHFFFAOYSA-N 0.000 description 1
- BSZQDFRBNZBYMQ-UHFFFAOYSA-N n-[4-[[3-(3-cyclopentyloxy-4-methoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]-2-(4-methylpiperazin-1-yl)acetamide Chemical compound COC1=CC=C(C=2CCC(=O)N(CC=3C=CC(NC(=O)CN4CCN(C)CC4)=CC=3)N=2)C=C1OC1CCCC1 BSZQDFRBNZBYMQ-UHFFFAOYSA-N 0.000 description 1
- RWHXIXAHQDVKLN-UHFFFAOYSA-N n-[4-[[3-(3-cyclopentyloxy-4-methoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]methanesulfonamide Chemical compound COC1=CC=C(C=2CCC(=O)N(CC=3C=CC(NS(C)(=O)=O)=CC=3)N=2)C=C1OC1CCCC1 RWHXIXAHQDVKLN-UHFFFAOYSA-N 0.000 description 1
- BQYXNMFWPXOBHV-UHFFFAOYSA-N n-[4-[[5-(3-ethoxy-4-methoxyphenyl)-2-oxo-6h-1,3,4-thiadiazin-3-yl]methyl]phenyl]-2-(4-methylpiperazin-1-yl)acetamide Chemical compound C1=C(OC)C(OCC)=CC(C=2CSC(=O)N(CC=3C=CC(NC(=O)CN4CCN(C)CC4)=CC=3)N=2)=C1 BQYXNMFWPXOBHV-UHFFFAOYSA-N 0.000 description 1
- MWJLPJRBACIIEQ-UHFFFAOYSA-N n-[[5-(3,4-dimethoxyphenyl)-6-ethyl-2-oxo-6h-1,3,4-thiadiazin-3-yl]-phenylmethyl]pyridine-4-carboxamide Chemical compound CCC1SC(=O)N(C(NC(=O)C=2C=CN=CC=2)C=2C=CC=CC=2)N=C1C1=CC=C(OC)C(OC)=C1 MWJLPJRBACIIEQ-UHFFFAOYSA-N 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10150517.5 | 2001-10-12 | ||
| DE10150517A DE10150517A1 (de) | 2001-10-12 | 2001-10-12 | Verwendung von Phosphodiesterase IV-Inhibitoren |
| PCT/EP2002/010507 WO2003032993A1 (de) | 2001-10-12 | 2002-09-19 | Verwendung von phosphodiesterase iv - inhibitoren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002338734A1 AU2002338734A1 (en) | 2003-07-03 |
| AU2002338734B2 true AU2002338734B2 (en) | 2007-11-08 |
Family
ID=7702358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002338734A Ceased AU2002338734B2 (en) | 2001-10-12 | 2002-09-19 | Use of phosphorodiesterase IV inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040235845A1 (enExample) |
| EP (1) | EP1435958A1 (enExample) |
| JP (1) | JP2005505604A (enExample) |
| KR (1) | KR20050028900A (enExample) |
| CN (1) | CN1564687A (enExample) |
| AR (1) | AR037741A1 (enExample) |
| AU (1) | AU2002338734B2 (enExample) |
| CA (1) | CA2460135C (enExample) |
| CZ (1) | CZ2004457A3 (enExample) |
| DE (1) | DE10150517A1 (enExample) |
| HU (1) | HUP0401641A3 (enExample) |
| MX (1) | MXPA04002639A (enExample) |
| NO (1) | NO20041938L (enExample) |
| SK (1) | SK1652004A3 (enExample) |
| WO (1) | WO2003032993A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023253A1 (en) * | 2003-09-05 | 2005-03-17 | Altana Pharma Ag | Use of pde4 inhibitors for the treatment of diabetes mellitus |
| US20080227790A1 (en) * | 2004-02-04 | 2008-09-18 | Altana Pharma Ag | Pyridazinone Derivatives and their Use as Pde4 Inhibitors |
| AU2005210042B2 (en) | 2004-02-04 | 2011-04-21 | Takeda Gmbh | 2-(piperidin-4-yl) -4, 5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors |
| MX2007010560A (es) | 2005-03-08 | 2008-02-21 | Nycomed Gmbh | Roflumilast para el tratamiento de diabetes mellitus. |
| DE102005055354A1 (de) * | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine |
| DE102005055355A1 (de) | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate |
| UA100497C2 (ru) | 2006-09-07 | 2013-01-10 | Никомед Гмбх | Комбинированное лечение сахарного диабета |
| BR112015019276A2 (pt) | 2013-02-19 | 2017-07-18 | Pfizer | compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios |
| US10131669B2 (en) | 2014-07-24 | 2018-11-20 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| EA031201B1 (ru) | 2014-08-06 | 2018-11-30 | Пфайзер Инк. | Соединения имидазопиридазина |
| RU2626677C1 (ru) * | 2016-03-09 | 2017-07-31 | Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" | Применение фармацевтической композиции 2-морфолино-5-фенил-6н-1,3,4-тиадиазина с аскорбиновой кислотой в качестве средства коррекции аллоксанового сахарного диабета |
| MA59016B1 (fr) * | 2022-12-30 | 2024-09-30 | Université Ibn Tofail | Nouveaux composés hétérocycliques de type 1,3,4-thiadiazines pour le traitement du diabète de type 2 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4134893A1 (de) * | 1991-10-23 | 1993-04-29 | Merck Patent Gmbh | Thiadiazinone |
| DE4310699A1 (de) * | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Thiadiazinone |
| US5786354A (en) * | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
| DE19502699A1 (de) * | 1995-01-28 | 1996-08-01 | Merck Patent Gmbh | Arylalkyl-thiadiazinone |
| DE19514568A1 (de) * | 1995-04-20 | 1996-10-24 | Merck Patent Gmbh | Arylalkyl-pyridazinone |
| DE19533975A1 (de) * | 1995-09-14 | 1997-03-20 | Merck Patent Gmbh | Arylalkyl-diazinone |
| GB9525262D0 (en) * | 1995-12-11 | 1996-02-07 | Bayer Ag | Heterocyclylcarbonyl substituted benzofuranyl-ureas |
| DE19604388A1 (de) * | 1996-02-07 | 1997-08-14 | Merck Patent Gmbh | Arylalkyl-diazinone |
| US5948911A (en) * | 1998-11-20 | 1999-09-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives |
-
2001
- 2001-10-12 DE DE10150517A patent/DE10150517A1/de not_active Withdrawn
-
2002
- 2002-09-19 WO PCT/EP2002/010507 patent/WO2003032993A1/de not_active Ceased
- 2002-09-19 CA CA2460135A patent/CA2460135C/en not_active Expired - Fee Related
- 2002-09-19 SK SK165-2004A patent/SK1652004A3/sk not_active Application Discontinuation
- 2002-09-19 HU HU0401641A patent/HUP0401641A3/hu unknown
- 2002-09-19 KR KR1020047005415A patent/KR20050028900A/ko not_active Withdrawn
- 2002-09-19 CZ CZ2004457A patent/CZ2004457A3/cs unknown
- 2002-09-19 MX MXPA04002639A patent/MXPA04002639A/es not_active Application Discontinuation
- 2002-09-19 CN CNA028198638A patent/CN1564687A/zh active Pending
- 2002-09-19 US US10/492,367 patent/US20040235845A1/en not_active Abandoned
- 2002-09-19 EP EP02777150A patent/EP1435958A1/de not_active Withdrawn
- 2002-09-19 AU AU2002338734A patent/AU2002338734B2/en not_active Ceased
- 2002-09-19 JP JP2003535796A patent/JP2005505604A/ja active Pending
- 2002-10-11 AR ARP020103824A patent/AR037741A1/es not_active Application Discontinuation
-
2004
- 2004-05-11 NO NO20041938A patent/NO20041938L/no unknown
Non-Patent Citations (1)
| Title |
|---|
| Expert Opinion on Investigational Drugs (1999) Vol.8 No.9 pp 1301-1325 * |
Also Published As
| Publication number | Publication date |
|---|---|
| SK1652004A3 (sk) | 2005-05-05 |
| HUP0401641A2 (hu) | 2004-11-29 |
| CA2460135C (en) | 2010-08-24 |
| MXPA04002639A (es) | 2004-06-07 |
| KR20050028900A (ko) | 2005-03-23 |
| US20040235845A1 (en) | 2004-11-25 |
| CA2460135A1 (en) | 2003-04-24 |
| EP1435958A1 (de) | 2004-07-14 |
| WO2003032993A1 (de) | 2003-04-24 |
| HUP0401641A3 (en) | 2007-02-28 |
| JP2005505604A (ja) | 2005-02-24 |
| NO20041938L (no) | 2004-05-11 |
| CZ2004457A3 (cs) | 2005-04-13 |
| DE10150517A1 (de) | 2003-04-17 |
| AR037741A1 (es) | 2004-12-01 |
| CN1564687A (zh) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002338734B2 (en) | Use of phosphorodiesterase IV inhibitors | |
| RU2324684C2 (ru) | Пиримидиновые производные | |
| EP2604595B1 (en) | Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity | |
| AU2001290229B2 (en) | Pyridazinones and triazinones and medicinal use thereof | |
| KR970015578A (ko) | 아릴알킬 디아진온 | |
| HRP960349A2 (en) | Therapeutic agents | |
| CA3066423A1 (en) | Compounds for modulating s1p1 activity and methods of using the same | |
| TW371657B (en) | Ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | |
| DE60114413T2 (de) | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten | |
| EA008865B1 (ru) | Производные 2-имино-4-оксотиазолидина | |
| WO2008148449A1 (de) | 2-oxo-3-benzyl-benzoxazol-2-one derivate und verwandte verbindungen als met-kinase inhibitoren zur behandlung von tumoren | |
| AU1998501A (en) | 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them | |
| DE4425145A1 (de) | Verwendung von Thiazol- und Thiadiazolverbindungen | |
| RU2219179C2 (ru) | Азациклические соединения, фармацевтические композиции | |
| SK287362B6 (sk) | Derivát arylalkanoylpyridazínu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje | |
| IL191360A (en) | Compounds Containing 5-Phenyl-6,3-Dihydro-2-Oxo-H6- [1,3,4] Thadiazines Converted, Process for their Preparation and Use for Drug Preparation | |
| NZ571441A (en) | Triazolone derivative | |
| EP0363796B1 (de) | Heterocyclische substituierte Alkoxycumarine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel | |
| CZ384698A3 (cs) | Antagonisté dopaminového receptoru D4 na bázi benzoxazinu | |
| CA2355243C (en) | Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives | |
| ZA200503383B (en) | 3,4,-Disubstituted pyrroles and their use in treating inflammatory diseases | |
| KR100384726B1 (ko) | 아릴알킬-티아디아지논유도체 | |
| AU2003210292A1 (en) | Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase | |
| US20090247516A1 (en) | 3- (benzo [d] [1,3] dioxol-5-ylmethyl) -4- (thio) oxo-2- (thio) oxo-azolidin-5-ylidene derivatives as antibacterial agents | |
| DE3508665A1 (de) | Heterocyclische sulfide und ihre anwendung als immunmodulatoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |